Sartar Therapeutics
PrivateLast Round
Early Funding
Oct 1, 2025
Est. Valuation
$15.59M
Total Funding Raised
$9.36M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Sartar Therapeutics operates in Healthcare & Life Sciences and is based in Helsinki. Its latest recorded funding round was an Early Funding round in October 2025.
Sartar Therapeutics is a pharmaceutical company that develops precision cancer treatments for gastrointestinal stromal tumors and other soft tissue sarcomas.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sartar Therapeutics Comparables
Compare Sartar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 74% | |
| Amira Therapeutics | 74% | |
| Degron Therapeutics | 72% |
For institutional investors. Book with your work email.
Sartar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 1, 2025 | ||||
| Debt | Sep 20, 2021 | ||||
| Seed | Oct 19, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sartar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Excedea Capital | Early Funding |
| Business Finland | Debt |
| Health Incubator Helsinki | Seed |
| NOME | Seed |
| Springvest | Early Funding, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 185% MoM, reaching 1K.
- Mar 1, 2026
Monthly visitors grew 961% MoM, from 67 to 711.
For institutional investors. Book with your work email.
Sartar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sartar Therapeutics's valuation, stock price, and market status.
Is Sartar Therapeutics a public or private company?
Sartar Therapeutics is a private company.
What is the current stock price of Sartar Therapeutics?
Sartar Therapeutics is a private company, so its shares have no public market price. Caplight tracks Sartar Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sartar Therapeutics worth (valuation)?
Sartar Therapeutics's valuation is estimated at $15.6M based on funding round data.
Can I buy Sartar Therapeutics stock?
Sartar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sartar Therapeutics's last funding round?
Sartar Therapeutics's most recent funding round was Early Funding on October 1, 2025.
Who are the main investors in Sartar Therapeutics?
Key investors in Sartar Therapeutics include Excedea Capital, Business Finland, Health Incubator Helsinki, NOME, Springvest.
Will Sartar Therapeutics IPO soon?
No public IPO plans have been announced for Sartar Therapeutics.
How can I track Sartar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Sartar Therapeutics's shares on secondary markets.